相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Francis W. Hunter et al.
BRITISH JOURNAL OF CANCER (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.
Laura Spring et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Jason J. Zoeller et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji et al.
LANCET ONCOLOGY (2019)
Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
Matthew Sung et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion
Mario Mauthe et al.
AUTOPHAGY (2018)
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Guangmin Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
Krista Kinneer et al.
CLINICAL CANCER RESEARCH (2018)
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance
Naoki Takegawa et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity
Carla Rios-Luci et al.
CANCER RESEARCH (2017)
Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells
Hongbin Wang et al.
CANCER SCIENCE (2017)
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Annette T. Byrne et al.
NATURE REVIEWS CANCER (2017)
Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Frank Loganzo et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
Miranda M. C. van der Lee et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985
Ronald C. Elgersma et al.
MOLECULAR PHARMACEUTICS (2015)
Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
Rocio Vicario et al.
PLOS ONE (2015)
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Gail D. Lewis Phillips et al.
CLINICAL CANCER RESEARCH (2014)
Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
Wim Dokter et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
'How can I halt thee?' The puzzles involved in autophagic inhibition
V. Vinod et al.
PHARMACOLOGICAL RESEARCH (2014)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Small-Molecule Multidrug Resistance-Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma
Catherine A. Burkhart et al.
CANCER RESEARCH (2009)
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2009)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
分享论文
